Melio is developing a rapid blood testing platform that utilizes proprietary assays and microfluidics to identify pathogens within hours, significantly reducing the time required for diagnosis compared to traditional blood cultures. This technology addresses the critical need for timely and accurate detection of bloodborne infections, particularly for vulnerable populations such as newborns in the NICU.
Funding
$7.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CXFounders
Product
Problem
Traditional blood cultures for identifying pathogens can take days to yield results, leading to delays in targeted treatment and potentially unnecessary antibiotic use. This is especially critical for vulnerable populations like newborns in the NICU, where rapid diagnosis is essential.
Solution
Melio is developing a culture-free, rapid blood testing platform that identifies pathogens within hours, significantly accelerating diagnosis compared to conventional methods. The platform integrates proprietary assays, state-of-the-art microfluidics, and machine-learning techniques to provide faster and more precise results. By eliminating the need for blood cultures, Melio enables clinicians to make informed treatment decisions on the same day, reducing the risk of ineffective or unnecessary antibiotic prescriptions. The system is designed to accurately identify frequently encountered and medically critical pathogens, with the ability to adapt and detect newly emerging threats through its continuously advancing technology.
Target Audience
The primary target audience includes healthcare providers in neonatal intensive care units (NICUs) and other settings where rapid pathogen identification is critical for timely treatment decisions.
Features
- Culture-free pathogen identification, delivering results in hours instead of days
- Integration of proprietary assays, microfluidics, and machine learning for rapid analysis
- Comprehensive pathogen detection, including frequently encountered and medically critical organisms
- Adaptable technology that adjusts to detect newly surfacing pathogens